NCT05936489

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: LENZ Therapeutics, Inc · Academic / Other
• Sex: All
• Age: 45 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.

Detailed description

To characterize the plasma pharmacokinetics and safety profile of LNZ101 and LNZ100 ophthalmic solutions in both eyes once a day for 8 days in healthy volunteers with presbyopia

Conditions

• Eye Diseases
• Presbyopia
• Refractive Errors
• Brimonidine Tartrate
• Aceclidine
• Ophthalmic Solutions

Interventions

Type	Name	Description
DRUG	Aceclidine + Brimonidine	LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
DRUG	Aceclidine	LNZ100 (Aceclidine) non-preserved ophthalmic solution

Timeline

• Start date: 2023-07-06
• Primary completion: 2023-10-03
• Completion: 2023-10-03
• First posted: 2023-07-07
• Last updated: 2023-10-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study